Quantcast

Latest Medical statistics Stories

2014-03-31 23:32:30

Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide. Reston, Virginia (PRWEB) March 31, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development today announced that it has agreed, subject to certain closing conditions, to be acquired by ICON plc, (NASDAQ: ICLR),...

2014-03-28 23:25:53

Verified Clinical Trials is proud to announce their presence at the Partnerships In Clinical Trials meeting in Las Vegas, Nevada to discuss the largest North American clinical research volunteer database that stops dual enrollment in clinical trials, while promoting patient safety and data quality. VCT is partnered with the world's largest pharmaceutical companies and CROs and continues to grow at an exponential pace in an effort to eliminate the professional research subject. Garden...

2014-03-21 08:24:29

DUBLIN, Mar. 21, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/4m4gr3/medical_device ) has announced the addition of the "Medical Device Clinical Studies - Understand How to Conduct Pre and Post Market Medical Device Clinical Studies (Course, London)" conference to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The Medical Device Clinical Studies Course will take place on the 1st & 2nd April 2014 at the...

2014-03-20 12:29:52

LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022 EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022SummaryChronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in...

2014-03-19 23:25:02

EPI-743 gains key regulatory endorsement. Downingtown, PA, (PRWEB) March 19, 2014 Edison Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Status to EPI-743 for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-awards-fast-track-status-to-edison-pharmaceuticals-epi-743-for-friedreichs-ataxia-250558901.html). This status will further accelerate the clinical development of EPI-743 now under way in two...

2014-03-18 23:26:23

Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, today announced the release of ADDPLAN® 6.1, the first statistical software to enable the use of surrogate endpoints to...

2014-03-13 23:27:22

JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the Company’s Investigational New Drug (IND) to conduct an initial Phase 3 clinical trial of JDP-205 in patients with acute urticaria associated with an acute allergic reaction has been cleared by the U.S. Food and Drug Administration (FDA). Blue Bell, PA (PRWEB) March 13, 2014 JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that the...

2014-03-13 08:28:16

Achieved Negative Predictive Value and Sensitivity ~97% and Specificity ~38% CASTLE ROCK, Colo., March 13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well,...

2014-03-12 23:30:50

Salus IRB maintains a legacy of 28 years of continuous service coupled with expanded capabilities. Austin, Texas (PRWEB) March 12, 2014 RCRC IRB announced today that its organization has changed its name to Salus IRB. The management, administrative staff, ownership structure, and review board memberships remain unchanged. “Clinical trials are more complicated, costly, and fast-paced than ever before,” says Salus President Dwight DuBois. “Salus recognizes this changing scientific...

2014-03-11 16:26:27

Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced fourth quarter and year end 2013 financial results. Clinical Developments and Anticipated Near-term Milestones -- Custirsen -- The SYNERGY Phase 3 trial is designed to...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related